Zora Biosciences Oy

Baker Heart and Diabetes Institute

Mika Hilvo

Reijo Laaksonen

Reini Hurme

Jonathan Shaw

Dianna Magliano

Kevin Huynh

Virve Vaeisaenen

Peter Meikle

The present disclosure relates to methods and uses involving the determination of lipid concentrations in order to diagnose, predict, prevent and/or treat one or more cardiovascular events in a subject. The methods include analyzing lipid concentrations of a sample from the subject and comparing them to a control.

Biomarkers for cardiovascular events

An in vitro method for assessing whether a subject is at risk to develop or is suffering from fatty liver disease comprising: (a) assaying a sample from said subject to determine a concentration of at least one fatty liver biomarker from Group E; (b) assaying a sample from said subject to determine a concentration of at least one fatty liver biomarker from Group F; and (c) determining that the subject is suffering from or is at an increased risk of developing fatty liver disease, if said sample contains an increased combination biomarker value of the at least one fatty liver biomarker from Group E and the at least one fatty liver biomarker from Group F, when compared to a control.

Methods for prediction and early detection of diabetes

The present description is related to the field of ovarian cancer diagnostics. It introduces novel biomarkers that can be used to detect presence of ovarian cancer and to provide a prognosis of the disease.

Methods for detecting ovarian cancer

The present invention inter alia provides a method, and use thereof, of predicting CV events such as AMI, ACS, stroke, and CV death by determining the concentration of at least one ceramide of Formula I or one lysophospholipid of Formula II and/or III and at least one lysophospholipid of Formula IV, V, VI, VII and/or VIII in a biological sample and comparing those concentrations to a control. Finding an increased concentration of the at least one Formula I ceramide or Formula II and/or III lysophospholipid and a decreased concentration of the at least one Formula IV, V, VI, VII and/or VIII lysophospholipid indicates that the subject has an increased risk of developing one or more CV events. The present disclosure also provides a method, and use thereof, of diagnosing subjects suffering acute ischemia. Also provided are kits and compositions comprising the same for use in predicting and/or diagnosing CV events.

Growing community of inventors

Helsinki, Finland

Mika Hilvo